Speaker illustration

Doctor Peter Kolkhof

BAYER HealthCare, Global Drug Discovery, Cardiology Research, Wuppertal (Germany)

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Event: ESC Congress 2021 - The Digital Experience

Topic: Target Organ Damage/Left Ventricular Hypertrophy

Session: Recent advances in diagnosis/treatment of hypertension


The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Targeting reverse remodelling in heart failure


Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes

Event: ESC CONGRESS 2016

Topic: Pharmacologic therapy

Session: Novel pharmacological therapy in chronic heart failure


This platform is supported by

logo Novo Nordisk